Skip to main
GRDN

GRDN Stock Forecast & Price Target

GRDN Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardian Pharmacy Service is positioned to benefit from the growing demand for long-term care pharmacy services, driven by an aging population and a fragmented industry ripe for consolidation. The company's strong financial position and proven operating model make it well-suited to capitalize on this opportunity. Additionally, favorable factors such as improved vaccine economics and increased Medicare Part D mix further support a positive outlook for the company's future growth and profitability. As a result, analysts have raised their estimates and price targets for Guardian Pharmacy Service, with one predicting a price target of $38. Based on these factors, the current outlook remains bullish and the stock is currently rated as a Buy.

Bears say

Guardian Pharmacy Service is experiencing positive growth with their recent acquisition and pipeline expansion. However, there are risks associated with their rating and price target, including potential regulatory changes and challenges with relationship management, staffing, supply chain, acquisitions, and reliance on technology. Their strong financial flexibility and technology capabilities stand out as differentiators in the market, but margin impacts from recent expansion may continue in the short term.

GRDN has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardian Pharmacy Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardian Pharmacy Services Inc (GRDN) Forecast

Analysts have given GRDN a Strong Buy based on their latest research and market trends.

According to 5 analysts, GRDN has a Strong Buy consensus rating as of Jun 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardian Pharmacy Services Inc (GRDN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.